MacroGenics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Maryland, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
9704 Medical Center Dr, Rockville, Maryl...Phone Number
(301) 251-5172Website
www.macrogenics.comRevenue
$157.1 MillionStock Symbol
MGNXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About MacroGenics
MacroGenics, Inc. is a publicly traded biotechnology company dedicated to discovering, developing, manufacturing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. The organization specializes in immuno-oncology and applies proprietary antibody engineering technologies to create medicines that enhance the immune system's ability to recognize and eliminate cancer cells. By integrating scientific research, translational medicine, clinical development, and biologics manufacturing, the company seeks to address significant unmet medical needs across multiple oncology indications.Explore more
MacroGenics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MacroGenics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if MacroGenics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once MacroGenics has new funding data
Check out if MacroGenics is spiking on competitors!
Earning: See what the market has to say on MacroGenics recently announced quarterly report
MacroGenics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when MacroGenics launches new products
Congratulate Masked Content for being promoted to Masked Content at MacroGenics
Click to see if MacroGenics had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to MacroGenics
Compare insights from companies similar to MacroGenics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$97.4M
201-500
Public
$237.2M
1997
John DesjarlaisExecutive Vice President & Research & Scientific Chief & Officer
Company Profile Activity
Activity Insights
MacroGenics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MacroGenics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MacroGenics.
MacroGenics financials insights
Gather financial insights about MacroGenics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2008
Series D
$25M
2010
Grant
$9.8M
2013
Stock Offering
$83.8M
2014
Stock Offering
$76.7M
2015
Stock Offering
$141M
2017
Stock Offering
$23.6M
2018
Stock Offering
$110M
MacroGenics Tech Stack
A closer look at the technologies used by MacroGenics
See more technologies
Most Recent Scoops
Open Position
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Event
Product Marketing, Events, Contingent Workforce, Sales, Outsourcing, Logistics / Supply Chain, Pharmaceuticals, Field /Outside Sales, Operations
Facilities Relocation / Expansion
MacroGenics is planning to move offices in July 2026. The move will impact approximately 135 employees at the existing office located at 9704 Medical Center Dr, Rockville, MD.
Facilities Relocation/Expansion
Open Position
MacroGenics News & Media
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific program under the companies’ 2022 collaboration agreement. The option exercise triggers a $10 million payment to MacroGenics.MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
ROCKVILLE, MD, July 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the ongoing Phase 1 study evaluating MGC026, a novel B7-H3-directed antibody-drug conjugate (ADC), incorporating a topoisomerase I inhibitor-based linker-payload, in patients with advanced solid tumors. MacroGenics plans to present dose escalation and prelMacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, today announced completion of the sale of MacroGenics’ good manufacturing practice (GMP) drug substance manufacturing operations to Bora.MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it will receive a $24.5 million regulatory milestone payment from Sanofi following the U.S. Food and Drug Administration’s (FDA) accelerated approval of TZIELD® (teplizumab-mzwv) to delay the decline in endogenous insulin production in children aged eight to 17 y
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MacroGenics
Sign Up For FreeTo access detailed company insights
MacroGenics, Inc. is a publicly traded biotechnology company dedicated to discovering, developing, manufacturing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. The organization specializes in immuno-oncology and applies proprietary antibody engineering technologies to create medicines that enhance the immun... Read More
